Reprogramming Myeloid Cells Enhances the Power of T-Cell Immunotherapy
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects of checkpoint blockade therapies.
A new antibody, H1A, shows promise for improving treatment outcomes.
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer.
Two research teams found that "first-responder" immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
The finding suggests that enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care for some cancers but may not have lasting effects.
Author's summary: Researchers enhance T-cell therapy by reprogramming myeloid cells.
More News
- Adobe’s experimental AI tool can edit entire videos using one frame
- Sinners: blood, blues and vampires - The Stute
- Sennheiser HDB 630 vs. Momentum 4: Premium Wireless Headphones Compared
- Wrexham 3-2 Coventry: Report, result, goals in Championship
- The Constitution Leaves No Room for Self-Serving “Insertions” | The Zimbabwe Mail
- The power of organising and how to win the outsourcing battle | Article | News | UNISON National
- Alito’s Oil Investments Pollute Contractor Accountability Case